Optimizing treatments in rare diseases: Will our evidence come from registry data?

Leukemia Research

Volumn 38, Issue 4, 2014, Pages 421-422

  Almeida, Antonio M ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE; RIBONUCLEOTIDE REDUCTASE; TRANSFER RNA;

ACUTE LEUKEMIA; APOPTOSIS; CANCER REGISTRY; CELL DIVISION; DNA SYNTHESIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE;

EID: 84897109389     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.01.015     Document Type: Editorial

References (15)

1. Glover A.B., Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep 1987, 71(10):959-964.
2. Kaminskas E., Farrell A.T., Wang Y.C., Sridhara R., Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005, 10(3):176-182.
3. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24(24):3895-3903.
4. Hollenbach P.W., Nguyen A.N., Brady H., Williams M., Ning Y., Richard N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010, 5(2):e9001.
5. Kuo H.K., Griffith J.D., Kreuzer K.N. 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res 2007, 67(17):8248-8254.
6. Glazer R.I., Hartman K.D. The comparative effects of 5-azacytidine and dihydro-5-azacytidine on 4 S and 5 S nuclear RNA. Mol Pharmacol 1980, 17(2):250-255.
7. Schaefer M., Pollex T., Hanna K., Lyko F. RNA cytosine methylation analysis by bisulfite sequencing. Nucleic Acids Res 2009, 37(2):e12.
8. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232.
9. Malcovati L., Hellstrom-Lindberg E., Bowen D., Ades L., Cermak J., del Cañizo C., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013, 122(17):2943-2964.
10. Bacher U., Haferlach T., Schnittger S., Kreipe H., Kroger N. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011, 153(2):149-167.
11. Kohlmann A., Grossmann V., Klein H.U., Schindela S., Weiss T., Kazak B., et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010, 28(24):3858-3865.
12. Tessema M., Langer F., Dingemann J., Ganser A., Kreipe H., Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003, 17(5):910-918.
13. Thorpe M., Montalvao A., Pierdomenico F., Moita F., Almeida A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res 2012, 36(8):1071-1073.
14. Ades L., Sekeres M.A., Wolfromm A., Teichman M.L., Tiu R.V., Itzykson R., et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013, 37(6):609-613.
15. Costa R., Abdulhaq H., Haq B., Shadduck R.K., Latsko J., Zenati M., et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011, 117(12):2690-2696.